Wolf, J. M., Gubert Borges, B., Pereira Fagundes, P., de Souza, V., Brenner, A., Petek, H., … Nasi, L. A. (2023). Adverse drug events, comorbidities, and older age are statistically more prevalent in COVID-19 hospitalized patients treated with remdesivir than tocilizumab in a private hospital from southern Brazil. Clinical and Biomedical Research, 43(3). https://doi.org/10.22491/2357-9730.129384